ARID4A

Across TCGA pan-cancer cohorts, ARID4A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARID4A data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARID4A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARID4A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where ARID4A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.475	0.229	.002	26	view →
HNSC	DFS	Tertile	All	0.371	0.914	.005	22	view →
LSCC	DFS	Median	All	0.834	0.592	.002	22	view →
CCRCC	OS	Tertile	All	1.000	0.544	.004	20	view →
LUAD	DFS	Quartile	All	0.827	0.368	.001	14	view →
GBM	OS	Median	All	0.599	0.451	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARID4A–PDAC (DFS)

Open the PDAC breakdown →